Justin Lessler
Auto-generated profile, based on publicly available information

Justin Lessler

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
SLStephen A. Lauer
Stephen A. Lauer
KGKyra H. Grantz
Kyra H. Grantz
QBQifang Bi
Qifang Bi
FJForrest K. Jones
Forrest K. Jones
QZQulu Zheng
Qulu Zheng
JLJustin Lessler
Justin Lessler
A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019. There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities. To estimate the length of the incubation period of COVID-19 and describe its public health implications. Pooled analysis of confirmed COVID-19 cases reported between 4 January 2020 and 24 February 2020. News reports and press releases from 50 provinces, regions, and countries outside Wuhan, Hubei province, China. Persons with confirmed SARS-CoV-2 infection outside Hubei province, China. Patient demographic characteristics and dates and times of possible exposure, symptom onset, fever onset, and hospitalization. There were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19. The median incubation period was estimated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days (CI, 8.2 to 15.6 days) of infection. These estimates imply that, under conservative assumptions, 101 out of every 10 000 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantine. Publicly reported cases may overrepresent severe cases, the incubation period for which may differ from that of mild cases. This work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS. Our results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases. U.S. Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, and Alexander von Humboldt Foundation.

1 August 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
QBQifang Bi
Qifang Bi
YWYongsheng Wu
Yongsheng Wu
SMShujiang Mei
Shujiang Mei
CYChenfei Ye
Chenfei Ye
XZXuan Zou
Xuan Zou
TFTiejian Feng
Tiejian Feng

10 July 2020 in Science
Verified
Journal Article
Open access
PDF file
HSHenrik Salje
Henrik Salje
CKCécile Tran Kiem
Cécile Tran Kiem
NLNoémie Lefrancq
Noémie Lefrancq
NCNoémie Courtejoie
Noémie Courtejoie
PBPaolo Bosetti
Paolo Bosetti
SCSimon Cauchemez
Simon Cauchemez
COVID-19 pandemic in France: Coronavirus disease 2019 (COVID-19) exacted a heavy toll in France during March and April 2020. Quarantine measures were effective in reducing transmission by 84%, and some relaxation of social isolation was expected in May. Salje et al. fit transmission models for the epidemic in France to hospital admissions. The authors forecast that 2.9 million people will have been infected by 11 May, representing 4.4% of the population—a value inadequate for herd immunity. Daily critical care hospitalizations should reduce from several hundreds to tens of cases, but control will remain a delicate balancing act. Any relaxation of lockdown in France will have to be carefully controlled and monitored to avoid undermining more optimistic forecasts. Science , this issue p. 208

3 December 2009 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
BLBrian K Lee
Brian K Lee
JLJustin Lessler
Justin Lessler
ESElizabeth A. Stuart
Elizabeth A. Stuart

1 May 2009 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JLJustin Lessler
Justin Lessler
NRNicholas G Reich
Nicholas G Reich
RBRon Brookmeyer
Ron Brookmeyer
TPTrish M Perl
Trish M Perl
KNKenrad E Nelson
Kenrad E Nelson
DCDerek At Cummings
Derek At Cummings

17 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AHAngkana T. Huang
Angkana T. Huang
BGBernardo Garcia-Carreras
Bernardo Garcia-Carreras
MHMatt D. T. Hitchings
Matt D. T. Hitchings
BYBingyi Yang
Bingyi Yang
LKLeah C. Katzelnick
Leah C. Katzelnick
DCDerek A. T. Cummings
Derek A. T. Cummings
Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARS-CoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV, MERS-CoV and endemic human coronaviruses (HCoVs). We reviewed 2,452 abstracts and identified 491 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While further studies of SARS-CoV-2 are necessary to determine immune responses, evidence from other coronaviruses can provide clues and guide future research.